Belden (BDC) Tops Q1 EPS by 1c; Issues Q2, FY12 Outlook
Tweet
Share
E-mailGet Alerts BDC Hot Sheet
Price: $110.92 -0.91%
Revenue Growth %: +37.7%
Financial Fact:
Continuing operations: 0.68
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +37.7%
Financial Fact:
Continuing operations: 0.68
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Belden (NYSE: BDC) reported Q1 EPS of $0.52, $0.01 better than the analyst estimate of $0.51. Revenue for the quarter came in at $464.3 million versus the consensus estimate of $451.83 million.
Belden sees Q2 2012 EPS of $0.73-$0.78, versus the consensus of $0.78. Belden sees Q2 2012 revenue of $500-$510 million, versus the consensus of $519.70 million.
Belden sees FY2012 EPS of $2.75-$2.90, versus the consensus of $2.77. Belden sees FY2012 revenue of $1.98-$2.02 billion, versus the consensus of $2.01 billion.
For earnings history and earnings-related data on Belden (BDC) click here.
Belden sees Q2 2012 EPS of $0.73-$0.78, versus the consensus of $0.78. Belden sees Q2 2012 revenue of $500-$510 million, versus the consensus of $519.70 million.
Belden sees FY2012 EPS of $2.75-$2.90, versus the consensus of $2.77. Belden sees FY2012 revenue of $1.98-$2.02 billion, versus the consensus of $2.01 billion.
For earnings history and earnings-related data on Belden (BDC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- UBS Reiterates Neutral Rating on Intuit (INTU), Says Investor Day Not 'Sentiment-Changing'
- B.Riley Assumes Anika Therapeutics (ANIK) at Buy
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
